Carl Cook

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley, Patricia McCoon, Carl Cook et al. · Journal for ImmunoTherapy of Cancer · 2018 · 288 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

Ezra E.W. Cohen, Kevin J. Harrington, David S. Hong et al. · Annals of Oncology · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

Judy Sing-Zan Wang, Serena De Vita, Janet L. Karlix et al. · Journal of Clinical Oncology · 2019 · 23 citations

Medicine, Pharmacokinetics, Pharmacology +14

Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)

Ezra E.W. Cohen, David S. Hong, T. Wise Draper et al. · Annals of Oncology · 2017 · 20 citations · Full text

Medicine, Oncology, Pharmacology +11

Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric <i>ErbB</i> mutations, in patients (pts) with advanced solid malignancies.

Alison M. Schram, Manish R. Patel, Shekeab Jauhari et al. · Journal of Clinical Oncology · 2021 · 17 citations

Medicine, Oncology, Pharmacology +14